Skip to content

PolitiKit

Lobbying by AstraZeneca Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

AstraZeneca Canada Inc.

Meetings this Parliament
63
With MPs
19
Since Nov 2021
134
Active registrations
1

Most recent reported meeting: Aug 28, 2026.

Registrations in effect

In-house (corporation) In effect since May 11, 2026

Filed by Gaby Bourbara, President

Lobbyists

  • Alex Romanovschi · Vice President, Scientific Affairs
  • Carlo Mastrangelo · Head - Corporate Communications - Corporate Affairs Canada
  • Deb Wong · Director, Payer Engagement
  • Denise Lacombe · Head of Legal
  • Gena Restivo · VP, Corporate Affairs & Sustainability
  • Heather McDonald · Vice President, Market Access and Pricing
  • Isabelle Gagnon · Lead - Federal Government Affairs
  • Jon Feairs · Director, Government Affairs & Public Policy
  • Noel Saraza · Senior Manager, Payer Relations
  • Pascal Soriot · Chief Executive
  • Tharany Ganesh · Head of Regulatory Affairs

Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Atlantic Canada Opportunities Agency (ACOA), Canada Economic Development for Quebec Regions, Canada Foundation for Innovation, Canada Revenue Agency (CRA), Canadian Institutes of Health Research (CIHR), Canadian International Trade Tribunal (CITT), Canadian Northern Economic Development Agency (CanNor), Competition Bureau Canada (COBU), Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), International Development Research Centre (IDRC), National Defence (DND), National Research Council (NRC), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Royal Canadian Mounted Police (RCMP), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)

What they're lobbying on (14)
  • Public health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as pandemic preparedness and RSV
  • Federally-funded public drug plans, including the Non-Insured Health Benefits program, Canadian Armed Forces Drug Benefit List and veteran programs, with respect to reimbursement for drug products for beneficiaries
  • Canada's Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework
  • Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
  • Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes
  • Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
  • Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
  • Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
  • Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
  • Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry
  • Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
  • Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
  • Annual federal Budgets and Budget updates relating to the biopharmaceutical industry.
  • Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits.

Registration 957438-15042-67. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by Gaby Bourbara (91), Kiersten Combs (43).

  • Reported by Gaby Bourbara · In-house (corporation)

    • Marjorie Michel · Minister of Health, Health Canada (HC)
    • Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    and 6 more
    • Rodrigo Arancibia · Director General, Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Read more

    Canada's Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Phillip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Stephanie Tanton · Assistance Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry Read more

    Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Paul Moen · Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
    Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry Read more

    Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Nasser Haidar · Senior Policy Advisor, Global Affairs Canada (GAC)
    Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry Read more

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Justine Frame · Special Assistant, Policy, Health Canada (HC)
    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Read more

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Read more

    Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs, Global Affairs Canada (GAC)
    • Marjorie Michel · Minister of Health, Health Canada (HC)
    • Karim Bardeesy · Member of Parliament
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    and 9 more
    • Martin Moen · Associate Assistant Deputy Minister, Global Affairs Canada (GAC)
    • Loris Mirella · Director, Intellectual Property, Trade Policy, Global Affairs Canada (GAC)
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Janice Charette · Chief Trade Negotiator to the US, Global Affairs Canada (GAC)
    • Shalene Curtis Micallef · Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Special Assistant, Policy, Health Canada (HC)
    • Daniel MacDonald · Director General, Health Canada (HC)
    Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

    Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Linda Lapointe · Member of Parliament
    • Simon Lacroix · Office Director, House of Commons
    Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry Read more

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Karen Fortin · Director, Pharmacy Benefits, Indigenous Services Canada (ISC)
    • Dylan Radke · Pharmacist, Indigenous Services Canada (ISC)
    • Bradley Bennet · Pharmacist, Indigenous Services Canada (ISC)
    • Mark Szeto · Policy Analyst, Indigenous Services Canada (ISC)
    and 2 more
    • Michelle Mujoombar · Manager, Indigenous Services Canada (ISC)
    • Peter Berry · Senior Policy Analyst and Science Advisor, Indigenous Services Canada (ISC)
    Federally-funded Public Drug Plans, including the Non Insured Health Benefits program, with respect to reimbursement for drug products for beneficiaries. Read more

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry Read more

    Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Hosai Zurmati Halim · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Rodrigo Arancibia · Director General, Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED)
    • Nadeen Abd El Aal · Senior Policy Analyst, Innovation, Science and Economic Development Canada (ISED)
    Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Greg Orencsak · Former Deputy Minister of Health, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Maxime Pedneault · Senior Advisor, Health Canada (HC)
    Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes Read more

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

    Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Yash Nanda · Senior Policy Advisor, Prime Minister's Office (PMO)
    Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

    Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Marc-André Blanchard · Chief of Staff, Prime Minister's Office (PMO)
    • Shaili Patel · Deputy Director of Policy, Prime Minister's Office (PMO)
    • Alexandre Boulé · Senior Advisor, Prime Minister's Office (PMO)
    Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

    Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry

    Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada

    Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Marjorie Michel · Minister of Health, Health Canada (HC)
    • Sandenga Yeba · Deputy Chief of Staff and Director of Policy, Health Canada (HC)
    • Justine Frame · Special Assistant, Policy, Health Canada (HC)
    • Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Read more

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

    Federally-funded Public Drug Plans, including the Non Insured Health Benefits program, with respect to reimbursement for drug products for beneficiaries.

    Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry

    Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework

    Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products

    Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes

    Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits.

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

    Annual federal Budgets and Budget updates relating to the biopharmaceutical industry.

    Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada

    Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry

    Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Ali Ehsassi · Parliamentary Secretary, Privy Council Office (PCO)
    • Miro Froehlich · Director of Policy, Privy Council Office (PCO)
    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Read more

    Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products

    Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry Read more

    Patent Act, Patented Medicines (Notice of Compliance) Regulations, Data Protection Regulation, Certificates of Supplementary Protection and related policies regarding the regulation of intellectual property for biopharmaceutical products, and maintaining international competitiveness.

    Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance.

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Karina Gould · Leader of the Government in the House of Commons
    Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry Read more

    Patent Act, Patented Medicines (Notice of Compliance) Regulations, Data Protection Regulation, Certificates of Supplementary Protection and related policies regarding the regulation of intellectual property for biopharmaceutical products, and maintaining international competitiveness.

    Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance.

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance. Read more

    Patented Medicine Prices Review Board (PMPRB) regarding development and implementation of guidelines to operationalize regulatory amendments.

    Patent Act, Patented Medicines (Notice of Compliance) Regulations, Data Protection Regulation, Certificates of Supplementary Protection and related policies regarding the regulation of intellectual property for biopharmaceutical products, and maintaining international competitiveness.

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Yash Nanda · Policy Advisor, Finance Canada (FIN)
    Patented Medicine Prices Review Board (PMPRB) regarding development and implementation of guidelines to operationalize regulatory amendments. Read more

    Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry

    Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance.

    Patent Act, Patented Medicines (Notice of Compliance) Regulations, Data Protection Regulation, Certificates of Supplementary Protection and related policies regarding the regulation of intellectual property for biopharmaceutical products, and maintaining international competitiveness.

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Jade Mallette · Chief of Staff to the Minister, Health Canada (HC)
    • Sandenga Yeba · Deputy Chief of Staff and Director of Policy, Health Canada (HC)
    Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry Read more

    Patented Medicine Prices Review Board (PMPRB) regarding development and implementation of guidelines to operationalize regulatory amendments.

    Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance.

    Patent Act, Patented Medicines (Notice of Compliance) Regulations, Data Protection Regulation, Certificates of Supplementary Protection and related policies regarding the regulation of intellectual property for biopharmaceutical products, and maintaining international competitiveness.

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance. Read more

    Patented Medicine Prices Review Board (PMPRB) regarding development and implementation of guidelines to operationalize regulatory amendments.

    Patent Act, Patented Medicines (Notice of Compliance) Regulations, Data Protection Regulation, Certificates of Supplementary Protection and related policies regarding the regulation of intellectual property for biopharmaceutical products, and maintaining international competitiveness.

    Official report

  • Reported by Gaby Bourbara · In-house (corporation)

    • Maggie Chi · MP & Parliamentary Secretary, Health Canada (HC)
    Patented Medicine Prices Review Board (PMPRB) regarding development and implementation of guidelines to operationalize regulatory amendments. Read more

    Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance.

    Patent Act, Patented Medicines (Notice of Compliance) Regulations, Data Protection Regulation, Certificates of Supplementary Protection and related policies regarding the regulation of intellectual property for biopharmaceutical products, and maintaining international competitiveness.

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.